Complexities of oestrogen in stroke

H.V.O. Carswell, I.M. Macrae, T.D. Farr

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Evidence exists for the potential protective effects of circulating ovarian hormones in stroke, and oestrogen reduces brain damage in animal ischaemia models. However, a recent clinical trial indicated that HRT (hormone-replacement therapy) increased the incidence of stroke in post-menopausal women, and detrimental effects of oestrogen on stroke outcome have been identified in a meta-analysis of HRT trials and in pre-clinical research studies. Therefore oestrogen is not an agent that can be promoted as a potential stroke therapy. Many published reviews have reported the neuroprotective effects of oestrogen in stroke, but have failed to include information on the detrimental effects. This issue is addressed in the present review, along with potential mechanisms of action, and the translational capacity of pre-clinical research.
Original languageEnglish
Pages (from-to)375-389
Number of pages14
JournalClinical Science
Volume118
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Estrogens
Stroke
Hormone Replacement Therapy
Neuroprotective Agents
Research
Action Potentials
Meta-Analysis
Ischemia
Animal Models
Clinical Trials
Hormones
Incidence
Brain
Therapeutics

Keywords

  • cardiovascular disease
  • cerebrovascular system
  • hormone-replacement therapy
  • oestrogen
  • selective oestrogen receptor modulator
  • stroke

Cite this

Carswell, H.V.O. ; Macrae, I.M. ; Farr, T.D. / Complexities of oestrogen in stroke. In: Clinical Science. 2009 ; Vol. 118, No. 6. pp. 375-389.
@article{a4f26dff562647aba096846b8f11d224,
title = "Complexities of oestrogen in stroke",
abstract = "Evidence exists for the potential protective effects of circulating ovarian hormones in stroke, and oestrogen reduces brain damage in animal ischaemia models. However, a recent clinical trial indicated that HRT (hormone-replacement therapy) increased the incidence of stroke in post-menopausal women, and detrimental effects of oestrogen on stroke outcome have been identified in a meta-analysis of HRT trials and in pre-clinical research studies. Therefore oestrogen is not an agent that can be promoted as a potential stroke therapy. Many published reviews have reported the neuroprotective effects of oestrogen in stroke, but have failed to include information on the detrimental effects. This issue is addressed in the present review, along with potential mechanisms of action, and the translational capacity of pre-clinical research.",
keywords = "cardiovascular disease, cerebrovascular system, hormone-replacement therapy, oestrogen, selective oestrogen receptor modulator, stroke",
author = "H.V.O. Carswell and I.M. Macrae and T.D. Farr",
year = "2009",
doi = "10.1042/CS20090018",
language = "English",
volume = "118",
pages = "375--389",
journal = "Clinical Science",
issn = "0143-5221",
number = "6",

}

Carswell, HVO, Macrae, IM & Farr, TD 2009, 'Complexities of oestrogen in stroke', Clinical Science, vol. 118, no. 6, pp. 375-389. https://doi.org/10.1042/CS20090018

Complexities of oestrogen in stroke. / Carswell, H.V.O.; Macrae, I.M.; Farr, T.D.

In: Clinical Science, Vol. 118, No. 6, 2009, p. 375-389.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Complexities of oestrogen in stroke

AU - Carswell, H.V.O.

AU - Macrae, I.M.

AU - Farr, T.D.

PY - 2009

Y1 - 2009

N2 - Evidence exists for the potential protective effects of circulating ovarian hormones in stroke, and oestrogen reduces brain damage in animal ischaemia models. However, a recent clinical trial indicated that HRT (hormone-replacement therapy) increased the incidence of stroke in post-menopausal women, and detrimental effects of oestrogen on stroke outcome have been identified in a meta-analysis of HRT trials and in pre-clinical research studies. Therefore oestrogen is not an agent that can be promoted as a potential stroke therapy. Many published reviews have reported the neuroprotective effects of oestrogen in stroke, but have failed to include information on the detrimental effects. This issue is addressed in the present review, along with potential mechanisms of action, and the translational capacity of pre-clinical research.

AB - Evidence exists for the potential protective effects of circulating ovarian hormones in stroke, and oestrogen reduces brain damage in animal ischaemia models. However, a recent clinical trial indicated that HRT (hormone-replacement therapy) increased the incidence of stroke in post-menopausal women, and detrimental effects of oestrogen on stroke outcome have been identified in a meta-analysis of HRT trials and in pre-clinical research studies. Therefore oestrogen is not an agent that can be promoted as a potential stroke therapy. Many published reviews have reported the neuroprotective effects of oestrogen in stroke, but have failed to include information on the detrimental effects. This issue is addressed in the present review, along with potential mechanisms of action, and the translational capacity of pre-clinical research.

KW - cardiovascular disease

KW - cerebrovascular system

KW - hormone-replacement therapy

KW - oestrogen

KW - selective oestrogen receptor modulator

KW - stroke

UR - http://www.clinsci.org/cs/118/cs1180375.htm

UR - http://dx.doi.org/10.1042/CS20090018

U2 - 10.1042/CS20090018

DO - 10.1042/CS20090018

M3 - Article

VL - 118

SP - 375

EP - 389

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 6

ER -